Anti-inflammatory pharmacotherapy during pregnancy

Bibliography

• DANNHARDT G, KIEFER W:Cyclooxygenase inhibitors — current status and future prospects. Eur J. Med. Chem. (2001) 36:109–126.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review on the classes of COX inhibitors and their action.
   Google Scholar
• DUBOIS RN, ABRAMSON SB,CROFFORD L et al.: Cyclooxygenase in biology and disease. FASEB J. (1998)12:1063–1073.
   PubMed Web of Science ®Google Scholar
• LIPSKY PE, BROOKS P, CROFFORD L et al.: Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Arch. Intern. Med.(2000) 160:913–920.
   PubMed Web of Science ®Google Scholar
• COOMARASAMY A, HONEST H, PAPAIOANNOU S, GEE H, KHAN KS:Aspn for prevention of preeclampsia in women with historical risk factors: a systematic review. °Intel-. Cynecel (2003) 101:1319–1332.
   Google Scholar
• BRANCH DW, KHAMASHTA MA:Antiphospholipid syndrome: obstetric diagnosis, management, and controversies.Obstet. Cynecel (2003) 101:1333–1344.
   Google Scholar
• YUSSOFF DAWOOD M: Nonsteroidal antiinflammatory drugs and reproduction.Am. J. Obstet. Cynecel (1993)169:1255–1265.
   PubMedGoogle Scholar
• OSTENSEN M: Prescribing in pregnancy — Rheumatological disorders. Best Pract Res Clio. Obstet. Cynecel (2001) 15:953–969.
   PubMedGoogle Scholar
• OSTENSEN M, FUHRER L,MATHIEU R, SEITZ M, VILLIGER PM: A prospective study of pregnant patientswith rheumatoid arthritis and ankylosing spondylitis using validated clinical instruments. Ann. Rheum. Dis. (In Press).
   Google Scholar
• PETRI M: Pregnancy in SLE. Bailhere's Clin. Rheumatol. (1998) 12:449–476.
   Google Scholar
• OLIW EH: Oxygenation ofpolyunsaturated fatty acids by cytochrome P-monooxygenases. Frog. Lipid Res. (1994) 33:329–354.
   PubMed Web of Science ®Google Scholar
• YOSHIDA S, AMANO H, HAYASHI I et al.: COX-2NEGF-dependent facilitation of tumor-associated angiogenesis and tumor growth in vivo. Lab. Invest. (2003) 83:1385–1394.
   PubMedGoogle Scholar
• CHANDRASEKHARAN NV, DAI H, ROOS KL et al.: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure and expression. Proc. Nati Acad. Sci. USA (2002) 99:13926–13931.
   PubMed Web of Science ®Google Scholar
• BOTTING R: COX-1 and COX-3 inhibitors. Thromb. Res. (2003) 110:269–272.
   PubMed Web of Science ®Google Scholar
• SIMMONS DL: Variants ofcyclooxygenase-1 and their roles in medicine. Thromb. Res. (2003) 110:265–268.
   PubMed Web of Science ®Google Scholar
• •Gives insight into effects of inhibition of distinct cydooxygenases by anti-inflammatory therapy.
   Google Scholar
• TEGEDER I, PFEILSCHIFTERJ, GEISSLINGER G: Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB (2001) 15:2057–2072.
   PubMed Web of Science ®Google Scholar
• MENDONCA LLF, KHAMASHTA MA, NELSON-PIERCY C, HUGHES GRV: Non-steroidal anti-inflammatory drugs as a possible cause for reversible infertility. Rheumatology (2000) 39:880–882.
   PubMedGoogle Scholar
• •Reviews clinical experience with NSAIDs and infertility.
   Google Scholar
• UHLER ML, HSU JW, FISHER SG, ZINAMAN MJ: The effect of nonsteroidal antiinflammatory drugs on ovulation: a prospective, randomized clinical trial. Feral. Sterd. (2001) 76:957–961.
   PubMedGoogle Scholar
• PALL M, FRIDEN BE,BRANNSTROM M: Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: a randomized double blind study. Hum. Reprod. (2001) 16:1323–1328.
   PubMed Web of Science ®Google Scholar
• REESE J, ZHAO X, MA WG,BROWN N, MAZIASZ TJ, DEY SK: Comparative analysis of pharmacologic and/or genetic disruption of cyclooxygenase-1 and cyclooxygenase-2function in female reproduction in mice.Endocrinology (2001) 142:3198–3206.
   PubMedGoogle Scholar
• SOOKVANICHSILP N, PULBUTR P: Anti-implantation effects of indomethacin and celecoxib in rats. Contraception (2002) 65:373–378.
   PubMed Web of Science ®Google Scholar
• CHENG JG, STEWART CL: Loss of cyclooxygenase-2 retards decidual growth but does not inhibit embryo implantation or development to term. Biol. Reprod. (2003) 68:401–404.
   PubMedGoogle Scholar
• JACOBSON RL, BREWER A, EIS A, SIDDIQI TA, MYATT L: Transfer of aspirin across the perfused human placental cotyledon. Am. .1 Obstet. Cynecol. (1991) 165:939–44.
   PubMed Web of Science ®Google Scholar
• LAMPELA ES, NUUTINEN LH, ALA-KOKKO TI et al.: Placental transfer of sulindac, sulindac sulfide, and indomethacin in a human placental perfusion model. Am. Obstet. Cynecol. (1999) 180(1 Pt 1):174–180.
   Google Scholar
• SIU SS, YEUNG JH, LAU TK: An in-vivo study on placental transfer of naproxen in early human pregnancy. Hum. Reprod. (2002) 17(4):1056–1059.
   PubMedGoogle Scholar
• SIU SS, YEUNG JH, LAU TK : A study on placental transfer of diclofenac in first trimester of human pregnancy.Hum. Reprod. (2000) 15(11):2423–2425.
   Google Scholar
• OSTENSEN M: Safety of non-steroidal anti-inflammatory drugs during pregnancy and lactation. Inflammopharmacology (1996) 4:31–41.
   Google Scholar
• MACONES GA, MARDER SJ, CLOTHIER B, STAMILIO DM: The controversy surrounding indomethacin for tocolysis. Am. Obstet. Cynecol. (2001) 184:264–272.
   PubMed Web of Science ®Google Scholar
• Drugs M pregnancy and lactation Oh ednIBriggs GG, Freeman RK, Yaffe SJ (Eds), Lippincott Williams & Wilkins, Philadelphia, USA (2002).
   Google Scholar
• •An excellent and updated source on drug therapy during pregnancy and lactation.
   Google Scholar
• NIELSEN GL, SORENSEN HT, LARSEN H, PEDERSEN L: Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study. Br. Med. (2001) 322:266–270.
   PubMed Web of Science ®Google Scholar
• CHAN LY, YUEN PM: Risk of miscarriage in pregnant users of NSAIDs. More information is needed to be able to interpret study's results. Br. Med.(2001) 322:1365–1366.
   Google Scholar
• LI DK, LIU L, ODOULI R: Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study.Br. Med. (2003) 327:368–373.
   PubMed Web of Science ®Google Scholar
• Birth defects and drugs M pregnancy Heinonen OP, Slone D, Shapiro S (Eds), Littleton Publishing Sciences Group, Littleton, MA, USA (1977):286–295.
   Google Scholar
• KALLEN B: The teratogenicity of antirheumatic drugs - what is the evidence? Scand.J. Rheumatol. (1998) 27\(Suppl. 107):119–124.
   Google Scholar
• •A critical survey on methodology searching for teratogenic effects of drugs.
   Google Scholar
• SKOMSVOLL JF, OSTENSEN M, IRGENS LM, BASTE V: Perinatal outcome in pregnancies of women with connective tissue disease and inflammatory rheumatic disease in Norway. Scand. Rheumatol. (1999) 28:352–356.
   PubMedGoogle Scholar
• WISE LD, CUKIERSKI MA, SHELLY LA, PATRICK DH: Effect of a COX-2 inhibitor, rofecoxib, on closure of the fetal rat ductus arteriosus.
   Google Scholar
• BURDAN F: Prenatal effects of DuP-697-the irreversible, highly selective cyclooxygenase-2 inhibitor.Reprod. Toxicol. (2000) 317:413–419.
   Google Scholar
• COOK JC, JACOBSON CF, GAO F, TASSINARI MS, HURTT ME, DESESSO JM: Analysis of the nonsteroidal anti-inflammatory drug literature for potential developmental toxicity in rats and rabbits. Birth Defects Res. Part B Dev. Reprod. Toxicol. (2003) 68:5–26.
   PubMedGoogle Scholar
• TASSINARI M, COOK JC, HURT ME: NSAIDs and developmental toxicity. Birth Defects Res. Part B Dev. Reprod. Toxicol. (2003) 68:3–4.
   PubMedGoogle Scholar
• CAPPON GD, COOK JC, HURTT ME: Relationship between cyclooxygenase 1 and 2 selective inhibitors and fetal development when administered to rats and rabbits during the sensitive periods for heart development and midline closure.Birth Defects Res. Part B Dev. Reprod. Toxicol. (2003) 68(1):47–56.
   Google Scholar
• SAD OVSKY Y, NELSON DM,MUGLIA LJ et al.: Effective diminution of amniotic prostaglandin production by selective inhibitors of cyclooxygenase Type 2. Am. .1. Obstet. Cynecol. (2000)182(2):370–376.
   Google Scholar
• LEWIS RB, SCHULMAN JD: Influence of acetylicsalicylic acid, an inhibitor of prostaglandin synthesis, on the duration ofhuman gestation and labour. Lancet (1973) 2:1159–1161.
   PubMed Web of Science ®Google Scholar
• SAWDY RJ, LYE S, FISK NM,BENNETT PR: A double-blindrandomised study of fetal side effects during and after short-term maternal administration of indomethacin, sulindac, and nimesulide for therapy of preterm labor. Am.j Obstet. Cynecol (2003) 188:1046–1051.
   PubMed Web of Science ®Google Scholar
• LOCATELLI A, VERGANI P, BELLINI P, STROBELT N, GHIDINI A: Can a cyclooxygenase type- 2 selective tocolytic agent avoid the fetal side effects of indomethacin? BJOG (2001) 108:325–326.
   PubMedGoogle Scholar
• STIKA CS, GROSS GA,LEGUIZAMON G et al: A prospective randomized safety trial of celecoxib for treatment of preterm labor. Jim. .1 °Enter Cynecol (2002) 187:653–660.
   Google Scholar
• STANFIELD KM, BELL RR,LISOWSKI AR, ENGLISH ML, SALDEEN SS, KHAN KN: Expression of cyclooxygenase-2 in embryonic and fetal tissues during organogenesis and late pregnancy. Birth Defects Res. Part A Clin. Mol Teratol (2003) 67:54–58.
   PubMedGoogle Scholar
• MOMMA K, TAKEUCHI H: Constriction of the ductus arteriosus by non-steroidal anti-inflammatory drugs. Prostaglandins (1983) 26:631–643.
   PubMed Web of Science ®Google Scholar
• LOFTIN CD, NORTON ME,MERRIL J, COOPER BAB, KULLER JA, CLYMAN RI: Neonatal complications after the administration of indomethacin for preterm labor. N Engl. .1. Med. (1993) 329:1602–1607.
   Google Scholar
• VERMILLION ST, SCARDO JA, LASHUS AG et al.: The effect of indomethacin tocolysis on fetal ductus arteriosus constriction with advancing gestational age. Am. Obstet. Cynecol (1997) 177:256–261.
   PubMed Web of Science ®Google Scholar
• VAN DEN VEYVER IB, MOISE KJ jR, OU CN, CARPENTER RJ JR: The effect of gestational age and fetal indomethacin levels on the incidence of constriction of the fetal ductus arteriosus. Obstet. Cynecol (1993) 82:500–503.
   Google Scholar
• TULZER G, GUDMUNDSSON S, SHARKEY AM, WOOD DC, COHEN AW, HUHTA JC: Doppler echocardiography of fetal ductus arteriosus constriction versus increased right ventricular output. I Am. Coll. Cardiol (1991) 18:532–536.
   PubMed Web of Science ®Google Scholar
• NORTON ME: Fetal effects of Indomethacin administration during pregnancy. Teratology (1997) 56:282–292.
   PubMedGoogle Scholar
• •Gestational age as a crucial requirement for adverse effects of NSAIDs on the fetal ductus arteriosus.
   Google Scholar
• ALANO MA, NGOUGMNA E, OSTREA EM jR, KONDURI GG: Analysis of nonsteroidal antiinflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics (2001) 107:519–523.
   PubMed Web of Science ®Google Scholar
• HICKOK DE, HOLLENBACH KA, REILLEY SF et al: The association between decreased amniotic fluid volume and treatment with nonsteroidal anti-inflammatory agents for preterm labor. Am. J. Obstet. Cynecol (1989) 160:1525–1531.
   PubMed Web of Science ®Google Scholar
• •A well-designed study revealing a strong relationship between anti-inflammatory drug consumption and pulmonary hypertension of the newborn.
   Google Scholar
• VAN DER HEIJDEN B, GUBLER MC: Renal failure in the neonate associated with in utero exposure to non-steroidal anti-inflammatory agents. Pediatr. Nephrol (1995) 9:675.
   PubMedGoogle Scholar
• LLANAS B, CAVERT MH, APERE H et al.: Les effets secondaires du ketoprof'ene apres exposition intra-utérine. Intérêt du dosage plasmatique. Arch. Pediatr. (1996) 3:248–253.
   PubMedGoogle Scholar
• KAJINO H, ROMAN C, CLYMAN RI: Renal effects of cyclooxygenase-2 inhibition in fetal lambs. Biol. Neonate (2002) 82:257–262.
   PubMedGoogle Scholar
• MERTZ HL, LIU J, VALEGO NK, STALLINGS SP, FIGUEROA JP, ROSE JC: Inhibition of cyclooxygenase-2: effects on renin secretion and expression in fetal lambs. Am. I Physiol Regal. Integr. Comp. Physiol (2003) 284:1010–1011.
   Google Scholar
• PERUZZI L, GIANOOGLIO B, PORCELLINI G, CONTI G, AMORO A, COPPO R: [Neonatal chronic kidney failure associated with cyclooxygenase-2 inhibitors administered during pregnancy]. Minerva Um] Nefrol. (2001) 53:113–116.
   PubMedGoogle Scholar
• KOZER E, MOLDOVAN COSTEI A, BOSKOVIC R, NULMAN I, NIKFAR S, KOREN G: Effects of aspirin consumption during pregnancy on pregnancy outcomes: meta-analysis. Birth Defects Res. Part B Dev. Reprod. Toxicol (2003) 68:70–84.
   PubMedGoogle Scholar
• VAINIO M, KUJANSUU E, ISO-MUSTAJARVI M, MAENPAA J: Low dose acetylsalicylic acid in preventionof pregnancy-induced hypertension and intrauterine growth retardation in women with bilateral uterine artery notches. BLOC (2002) 109:161–167.
   Google Scholar
• •A comprehensive analysis comprising a large number of exposed pregnancies.
   Google Scholar
• OZTURK 0, GREAVES M, TEMPLETON A: Aspirin dilemma. Remodelling the hypothesis from a fertility perspective. Hum. Reprod. (2002) 17:1146–1148.
   Google Scholar
• HERTZ-PICCIOTTO I,HOPENHAYN-RICH C, GOLUB M, HOOPER K: The risks and benefits of taking aspirin during pregnancy. Epidemiol Rev (1990) 12:108–148.
   PubMed Web of Science ®Google Scholar
• SLONE D, HEINONEN OP, KAUFMAN DW, SISKIND V, MONSON RR, SHAPIRO S: Aspirin and congenital malformations. Lancet (1976) 2:1373–1375.
   PubMedGoogle Scholar
• •A detailed survey of the effects of high- and low-dose aspirin during pregnancy.
   Google Scholar
• KARON A, HONEIN MA, MOORE CA: Maternal febbrile illnesses, medication use, and the risk of congenital renal anomalies. Birth Defects Res. Part A Clin. Mol. Teratol (2003) 67:911–918.
   PubMedGoogle Scholar
• KOZER E, SHEKOUFEH N, COSTEI A,BOSKOVIC R, NULMAN I, KOREN G: Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. Am. Obstet. Cynecol (2002) 187:1623–1630.
   PubMed Web of Science ®Google Scholar
• WERLER MM, SHEEHAN JE,MITCHELL AA: Maternal medication use and risks of gastroschisis and small intestinal atresia. Arn. Epidemiol (2002) 155:26–31.
   PubMed Web of Science ®Google Scholar
• •A detailed meta-analysis including a great number of exposed pregnancies.
   Google Scholar
• MARTINEZ-FRIAS ML,RODRIGUEZ-PINILLA E, PRIETO L: Prenatal exposure to salicylates and gastroschisis: a case-control study. Teratology (1997) 56(4):241–243.
   PubMedGoogle Scholar
• WERLER MM, MITCHELL AA, SHAPIRO S: First trimester maternal medication use in relation to gastroschisis. Teratology (1992) 45(4):361–367.
   PubMedGoogle Scholar
• STUART MJ, GROSS SJ, ELRAD H, GRAEBER JE: Effects of acetylsalicylic-acid ingestion on maternal and neonatal hemostasis. N Engl. Med. (1982) 307:909–912.
   PubMed Web of Science ®Google Scholar
• RUMACK CM, GUGGENHEIM MA, RUMACK BH et al.: Neonatal intracranial hemorrhage and maternal use of aspirin. Obstet. Cynecol (1981) 58(Suppl.):52S–56S.
   Google Scholar
• LEONHARDT A, BERNERT S, WATZER B, SCHMITZ-ZIEGLER G, SEYBERTH HW: Low-dose aspirin in pregnancy: maternal and neonatal aspirin concentrations and neonatal prostanoid formation. Pediatrics (2003) 111:e77–e81.
   Google Scholar
• DI SESSA TG, MORETTI ML, KHOURY A et al.: Cardiac function in fetuses and newborns exposed to low-dose aspirin during pregnancy. Am.,/ Obstet. Gynecol (1994) 171:892–900.
   PubMed Web of Science ®Google Scholar
• PINSKY L, DIGEORGE AM: Cleft palate in the mouse: a teratogenic index of glucocorticoid potency. Science (1965) 147:402–403.
   PubMed Web of Science ®Google Scholar
• FRASER FC, SAJO0 A: Teratogenic potential of corticosteroids in humans. Teratology (1995) 51:45–46.
   PubMedGoogle Scholar
• RODRIGUEZ-PINILLA E,MARTINEZ-FRIAS ML: Corticosteroids during pregnancy and oral clefts: a case-control study. Teratology (1998) 58:2–5.
   PubMedGoogle Scholar
• CARMICHAEL SL, SHAW GM: Maternal corticosteroid use and risk of selected congenital anomalies. Teratology (1999) 86:242–244.
   Google Scholar
• PARK-WYLLIE L, MAZZOTTA P, PASTUSZAK A et al.: Birth defects after maternal exposure to corticosteroids: Prospective cohort study and meta-analysis of epidemiological studies. Teratology (2000) 62:385–392.
   PubMedGoogle Scholar
• EDWARDS MJ, AGHO K, ATTIA J et al:Case-control study of cleft lip or palate after maternal use of topical corticosteroids during pregnancy. Am. I Med. Genet. (2003) 120:459–463.
   Google Scholar
• •Comparison of the results of a prospective, controlled study and a meta-analysis regarding teratogenic potential of glucocorticosteroids.
   Google Scholar
• MYGIND H, THULSTRUP AM, PEDERSEN L, LARSEN H: Risk of intrauterine growth retardation, malformations, and other birth outcomes in children after topical use of corticosteroid in pregnancy. Acta °Enter Gynecol Scand. (2002) 81:234–239.
   PubMed Web of Science ®Google Scholar
• CZEIZEL AE, ROCKENBAUER M: Population-based case-control study of teratogenic potential of corticosteroids. Teratology (1997) 56:335–340.
   Google Scholar
• PRADAT P, ROBERT-GNANSIA E, DI TANNA GL et al.: First trimester exposure to corticosteroids and oral clefts. Birth Defects Res. Part A Clin. Mol. Teratol (2003) 67:968–970.
   PubMed Web of Science ®Google Scholar
• •A detailed study of systemic and topical corticosteroid treatment during pregnancy based on a National Congenital Abnormality Registry.
   Google Scholar
• REINISCH JM, SIMON NG: Prenatal exposure to prednisone in humans and animals retards intrauterine growth. Science (1978) 202:436–438.
   PubMed Web of Science ®Google Scholar
• SCOTT JR: Fetal growth retardation associated with maternal administration of immunosuppressives. Am. .1. °Enter Gynecol (1977) 128:668–676.
   PubMed Web of Science ®Google Scholar
• CZEIZEL AE: Birth weight, gestational age and medications during pregnancy.Int. J. Gynaecol °Enter (1998) 60:245–249.
   PubMedGoogle Scholar
• COWCHOCK FS, REECE EA, BALABAN D, BRANCH DW, PLOUFFE L: Repeated fetal losses associated with antiphospholipid antibodies; a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am. I Obstet. Gynecol (1992) 166:1318–1323.
   PubMed Web of Science ®Google Scholar
• CEDERQVIST LL, MERKATZ IR, LITWIN SD: Fetal immunoglobin synthesis following maternal immunosuppression. Am. °Enter Gynecol (1977) 129:687–690.
   PubMed Web of Science ®Google Scholar
• COTE CJ, MEUWISSEN HG,PICKERING RJ: Effects on the neonate of prednisone and azathioprine administered to the mother during pregnancy. Pediatr. (1974) 85:324–328.
   Google Scholar
• SCHMIDT PL, SIMS ME,STRASSNER HT et al.: Effect of antepartum glucorticoid administration upon neonatal respiratory distress syndrome and perinatal infection. Am. Obstet. Gynecol (1984) 178:178–1786.
   Google Scholar
• CLARK DA, BANWATT D,CHAOUAT G: Effect of prostaglandin synthesis inhibitors on spontaneous andendotwdn-induced abortion in mice. Reprod. Immunol (1993) 24(1):29–44.
   PubMedGoogle Scholar
• TINCANI A, BRANCH W, LEVY RA et al.: Treatment of pregnant patients with antiphospholipid sydrome. Lupus (2003) 12:524–529.
   PubMed Web of Science ®Google Scholar
• PAR G, BARTOK B,SZEKERES-BARTHO J: Cyclooxygenase is involved in the effects of progesterone-induced blocking factor on the production of interleukin 12. Am. .1. Obstet. Gynecol (2000) 183:126–130.
   Google Scholar
• •A comprehensive approach to the treatment of antiphospholipid syndrome in pregnancy.
   Google Scholar
• OSTENSEN M, OSTENSEN H: Ankylosing spondylitis - the female aspect. Rheumatol (1998) 25:120–124.
   Google Scholar
• ZAW W, GAGNON R, DA SILVA 0: The risks of adverse neonatal outcome among preterm small for gestational age infants according to neonatal versus fetal growth standards. Pediatrics (2003) 111:1273–1277.
   PubMed Web of Science ®Google Scholar
• BURTON PJ, WADDELL BJ: Dual function of 1113-hydroxysteroid dehydrogenase in placenta: modulating placental glucocorticoid passage and local steroid action. Biol. Reprod. (1999) 60:234–240.
   PubMed Web of Science ®Google Scholar
• BENEDIKTSSON R, LINDSAY RS, NOBLE J, SECKL JR, EDWARDS CRW: Glucocorticoid exposure in utero: new model for adult hypertension.Lancet (1993) 341:339–341.
   PubMed Web of Science ®Google Scholar